|
US7884119B2
(en)
*
|
2005-09-07 |
2011-02-08 |
Rigel Pharmaceuticals, Inc. |
Triazole derivatives useful as Axl inhibitors
|
|
JP2010514810A
(ja)
|
2006-12-29 |
2010-05-06 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
Ａｘｌインヒビターとして有用な置換トリアゾール
|
|
AU2007342005A1
(en)
*
|
2006-12-29 |
2008-07-10 |
Rigel Pharmaceuticals, Inc. |
N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
|
|
EP2114954B1
(en)
|
2006-12-29 |
2013-02-13 |
Rigel Pharmaceuticals, Inc. |
Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
|
|
ES2404668T3
(es)
|
2006-12-29 |
2013-05-28 |
Rigel Pharmaceuticals, Inc. |
Triazoles sustituidos con arilo bicíclico puenteado y heteroarilo bicíclico puenteado, útiles como agentes inhibidores del axl
|
|
PT2078010E
(pt)
|
2006-12-29 |
2014-05-07 |
Rigel Pharmaceuticals Inc |
Triazoles substituídos com heteroarilos policíclicos úteis como inibidores de axl
|
|
CA2704052C
(en)
*
|
2007-10-26 |
2015-04-21 |
Rigel Pharmaceuticals, Inc. |
Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
|
|
HUE030912T2
(en)
|
2008-02-15 |
2017-06-28 |
Rigel Pharmaceuticals Inc |
Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
|
|
US8431594B2
(en)
|
2008-07-09 |
2013-04-30 |
Rigel Pharmaceuticals, Inc. |
Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors
|
|
JP5592884B2
(ja)
*
|
2008-07-09 |
2014-09-17 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
Ａｘｌ阻害剤として有用な多環式ヘテロアリール置換トリアゾール
|
|
JP4644273B2
(ja)
*
|
2008-07-15 |
2011-03-02 |
本田技研工業株式会社 |
車両周辺監視装置
|
|
RU2555326C2
(ru)
|
2009-01-16 |
2015-07-10 |
Риджел Фармасьютикалз, Инк. |
ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА
|
|
MY165215A
(en)
*
|
2012-01-31 |
2018-03-09 |
Daiichi Sankyo Co Ltd |
Pyridone derivatives
|
|
WO2013162061A1
(ja)
*
|
2012-04-26 |
2013-10-31 |
第一三共株式会社 |
二環性ピリミジン化合物
|
|
WO2014018535A1
(en)
|
2012-07-25 |
2014-01-30 |
Salk Institute For Biological Studies |
Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
|
|
CN105916506B
(zh)
|
2013-11-20 |
2020-01-07 |
圣诺康生命科学公司 |
作为tam家族激酶抑制剂的喹唑啉衍生物
|
|
CN105764514B
(zh)
|
2013-11-27 |
2019-07-12 |
圣诺康生命科学公司 |
作为tam族激酶抑制剂的氨基吡啶衍生物
|
|
TWI690525B
(zh)
*
|
2014-07-07 |
2020-04-11 |
日商第一三共股份有限公司 |
具有四氫吡喃基甲基之吡啶酮衍生物及其用途
|
|
US9840503B2
(en)
|
2015-05-11 |
2017-12-12 |
Incyte Corporation |
Heterocyclic compounds and uses thereof
|
|
GB201509338D0
(en)
|
2015-05-29 |
2015-07-15 |
Bergenbio As |
Combination therapy
|
|
WO2017027717A1
(en)
|
2015-08-12 |
2017-02-16 |
Incyte Corporation |
Bicyclic fused pyrimidine compounds as tam inhibitors
|
|
US10053465B2
(en)
|
2015-08-26 |
2018-08-21 |
Incyte Corporation |
Pyrrolopyrimidine derivatives as TAM inhibitors
|
|
ES2839212T3
(es)
|
2015-09-29 |
2021-07-05 |
Inst Nat Sante Rech Med |
Métodos para determinar el estado metabólico de linfomas B
|
|
WO2017118634A1
(en)
|
2016-01-04 |
2017-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
|
|
ES2896079T3
(es)
|
2016-02-26 |
2022-02-23 |
Ono Pharmaceutical Co |
Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario
|
|
CN114456176B
(zh)
|
2016-03-28 |
2024-08-30 |
因赛特公司 |
作为tam抑制剂的吡咯并三嗪化合物
|
|
JP7393209B2
(ja)
*
|
2017-01-26 |
2023-12-06 |
センパー フォーティス ソリューションズ リミテッド ライアビリティ カンパニー |
マルチテナントクラウドにおける複数のシングルレベルセキュリティ（ｍｓｌｓ）
|
|
EP3600427A1
(en)
|
2017-03-24 |
2020-02-05 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
|
EP3673907A4
(en)
|
2017-08-23 |
2020-08-19 |
ONO Pharmaceutical Co., Ltd. |
CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT
|
|
KR102739325B1
(ko)
|
2017-09-27 |
2024-12-09 |
인사이트 코포레이션 |
Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
|
|
US11826363B2
(en)
|
2017-10-13 |
2023-11-28 |
Ono Pharmaceutical Co., Ltd. |
Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
|
|
EP3735590A1
(en)
|
2018-01-04 |
2020-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
|
EP3756012A1
(en)
|
2018-02-21 |
2020-12-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
|
|
US11241438B2
(en)
|
2018-06-29 |
2022-02-08 |
Incyte Corporation |
Formulations of an AXL/MER inhibitor
|
|
US20230183379A1
(en)
|
2018-11-20 |
2023-06-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
|
WO2020127411A1
(en)
|
2018-12-19 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
|
EP3918332B1
(en)
|
2019-01-30 |
2025-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
|
|
US20220117911A1
(en)
|
2019-02-04 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
|
US20220098674A1
(en)
|
2019-02-13 |
2022-03-31 |
Inserm (Institut National De La Santé Et Dr La Recherch Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
|
EP3942045A1
(en)
|
2019-03-21 |
2022-01-26 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
WO2020221796A1
(en)
|
2019-04-30 |
2020-11-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
GB201912059D0
(en)
|
2019-08-22 |
2019-10-09 |
Bergenbio As |
Combaination therapy of a patient subgroup
|
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
WO2021064180A1
(en)
|
2019-10-03 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
|
US20240301497A1
(en)
|
2019-10-17 |
2024-09-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing nasal intestinal type adenocarcinomas
|
|
US20240122938A1
(en)
|
2019-10-29 |
2024-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating uveal melanoma
|
|
EP4054579A1
(en)
|
2019-11-08 |
2022-09-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
|
CA3164754A1
(en)
|
2019-12-19 |
2021-06-24 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and vaccine compositions to treat cancers
|
|
EP4090770A1
(en)
|
2020-01-17 |
2022-11-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
WO2021156360A1
(en)
|
2020-02-05 |
2021-08-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
|
|
WO2021170777A1
(en)
|
2020-02-28 |
2021-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, prognosing and managing treatment of breast cancer
|
|
PH12022552347A1
(en)
|
2020-03-06 |
2024-01-29 |
Incyte Corp |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
|
GB202004189D0
(en)
|
2020-03-23 |
2020-05-06 |
Bergenbio As |
Combination therapy
|
|
IL297132A
(en)
|
2020-04-08 |
2022-12-01 |
Bergenbio Asa |
axl inhibitors for antiviral therapy
|
|
GB202006072D0
(en)
|
2020-04-24 |
2020-06-10 |
Bergenbio Asa |
Method of selecting patients for treatment with cmbination therapy
|
|
JP7856627B2
(ja)
|
2020-07-28 |
2026-05-11 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンを予防及び処置するための方法及び組成物
|
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
|
EP4244391A1
(en)
|
2020-11-16 |
2023-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
EP4244392A1
(en)
|
2020-11-16 |
2023-09-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
WO2022194908A1
(en)
|
2021-03-17 |
2022-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
GB202104037D0
(en)
|
2021-03-23 |
2021-05-05 |
Bergenbio Asa |
Combination therapy
|
|
EP4326903A1
(en)
|
2021-04-23 |
2024-02-28 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
|
US20240426823A1
(en)
|
2021-11-03 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
|
WO2023118165A1
(en)
|
2021-12-21 |
2023-06-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
GB202209285D0
(en)
|
2022-06-24 |
2022-08-10 |
Bergenbio Asa |
Dosage regimen for AXL inhibitor
|
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
|
WO2024051667A1
(zh)
*
|
2022-09-05 |
2024-03-14 |
南京正大天晴制药有限公司 |
具有axl抑制活性的取代三唑化合物
|
|
WO2024056716A1
(en)
|
2022-09-14 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
|
|
WO2024084034A1
(en)
|
2022-10-21 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
|
WO2024200571A1
(en)
|
2023-03-28 |
2024-10-03 |
Institut National de la Santé et de la Recherche Médicale |
Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
|
|
WO2024231384A1
(en)
|
2023-05-10 |
2024-11-14 |
Institut National de la Santé et de la Recherche Médicale |
Compositions for treating senescence related disease
|
|
WO2024236156A1
(en)
|
2023-05-17 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cathepsin-d antibodies
|
|
WO2024245951A1
(en)
|
2023-05-26 |
2024-12-05 |
Institut National de la Santé et de la Recherche Médicale |
Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
|
|
WO2024256635A1
(en)
|
2023-06-15 |
2024-12-19 |
Institut National de la Santé et de la Recherche Médicale |
Dpm1 inhibitor for treating cancer
|
|
WO2025068180A1
(en)
|
2023-09-25 |
2025-04-03 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of cancer by targetting cancer - associated fibroblasts
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
WO2025078632A1
(en)
|
2023-10-12 |
2025-04-17 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from cancer
|
|
WO2025132479A1
(en)
|
2023-12-18 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Flt3 inhibitor for modulating macrophages polarization
|
|
WO2025132770A1
(en)
|
2023-12-22 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Affitins for the treatment of cancer
|
|
WO2025210123A1
(en)
|
2024-04-03 |
2025-10-09 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating cancers
|
|
WO2025219330A1
(en)
|
2024-04-15 |
2025-10-23 |
Institut National de la Santé et de la Recherche Médicale |
Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
|
|
WO2025228998A1
(en)
|
2024-04-30 |
2025-11-06 |
Institut National de la Santé et de la Recherche Médicale |
Use of hdac4 inhibitors for the treatment of melanoma
|
|
WO2025247829A1
(en)
|
2024-05-27 |
2025-12-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating prostate cancer
|
|
WO2026013071A1
(en)
|
2024-07-09 |
2026-01-15 |
Institut National de la Santé et de la Recherche Médicale |
Setdb1 inhibitor for use in the treatment of uveal melanoma
|